ABX203

[Airquake]

NEW YORK, NY / ACCESSWIRE / March 1, 2016 / LifeSci Capital, LLC, a research-driven investment bank with deep domain expertise in the life sciences sector, today announced that it has initiated coverage of Abivax (Euronext Paris: ABVX.PA), a biotechnology company that is developing novel therapies to treat serious infectious diseases. The Company is currently focused on treatments for chronic hepatitis B and human immunodeficiency virus (HIV) infection.

ABX203 is a therapeutic vaccine candidate in development for chronic hepatitis B consisting of virus-like particles (VLPs) that contain both HBV surface antigen (HBsAg) and HBV core antigen (HBcAg). The Company licensed ABX203 from the Center for Genetic Engineering and Biotechnology (CIGB) in 2013, providing the Company with exclusive rights to market ABX203 in Europe, Australia, New Zealand, select Asian countries, and most of Africa. Abivax is currently conducting a Phase II/III trial evaluating the safety and efficacy of ABX203 for the treatment of patients with chronic hepatitis B. The trial is fully enrolled and the Company expects to report data in the fourth quarter of 2016. Data from this pivotal trial could support approval in certain countries as early as 2018 and may also allow Abivax to pursue partnership opportunities for EU and Japanese territories. ABX203 has the potential to be an integral component of a multiple treatment approach that will likely be required for a functional HBV cure.